DB15082Investigational
Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
- Mechanism
- Curator reviewed
Pharmacologically active on Macrophage colony-stimulating factor 1 receptor
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Cabiralizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account